These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16913647)

  • 21. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):273. PubMed ID: 20224545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent trends in meningococcal epidemiology and current vaccine recommendations.
    Baltimore RS
    Curr Opin Pediatr; 2006 Feb; 18(1):58-63. PubMed ID: 16470164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current safety issues with quadrivalent meningococcal conjugate vaccines.
    Myers TR; McNeil MM
    Hum Vaccin Immunother; 2018 May; 14(5):1175-1178. PubMed ID: 28934061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Travelers' protection against meningococcal disease: a new vaccine option.
    Black S
    J Travel Med; 2010; 17 Suppl():18-25. PubMed ID: 20849429
    [No Abstract]   [Full Text] [Related]  

  • 26. Optimizing protection against meningococcal disease.
    Reisinger KS; Black S; Stoddard JJ
    Clin Pediatr (Phila); 2010 Jun; 49(6):586-97. PubMed ID: 20089551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.
    Findlow H; Borrow R
    Adv Ther; 2013 May; 30(5):431-58. PubMed ID: 23712402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
    Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.
    Ramsay ME; Andrews N; Kaczmarski EB; Miller E
    Lancet; 2001 Jan; 357(9251):195-6. PubMed ID: 11213098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine.
    Mehlhorn AJ; Balcer HE; Sucher BJ
    Ann Pharmacother; 2006 Apr; 40(4):666-73. PubMed ID: 16595570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2005 Aug; 116(2):496-505. PubMed ID: 15995007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccines for Prevention of Group B Meningococcal Disease: Not Your Father's Vaccines.
    Harrison LH
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S345-54. PubMed ID: 26590434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal serogroup C serum and salivary antibody responses to meningococcal quadrivalent conjugate vaccine in Saudi Arabian adolescents previously vaccinated with bivalent and quadrivalent meningococcal polysaccharide vaccine.
    Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Oster P; Borrow R
    Vaccine; 2014 Sep; 32(43):5715-21. PubMed ID: 25151042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in meningococcal C epidemiology and vaccine effectiveness after vaccine introduction and schedule modification.
    Garrido-Estepa M; León-Gómez I; Herruzo R; Cano R
    Vaccine; 2014 May; 32(22):2604-9. PubMed ID: 24662700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reconsideration of the use of meningococcal polysaccharide vaccine.
    Granoff DM; Pollard AJ
    Pediatr Infect Dis J; 2007 Aug; 26(8):716-22. PubMed ID: 17848884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meningococcal vaccine for infants?
    Campos-Outcalt D
    J Fam Pract; 2012 Aug; 61(8):482-4. PubMed ID: 22871657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.